Status:

ACTIVE_NOT_RECRUITING

Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection

Lead Sponsor:

Cedars-Sinai Medical Center

Conditions:

Rejection Chronic Renal

Kidney Transplant Rejection

Eligibility:

All Genders

18+ years

Brief Summary

Our group recently reported that tocilizumab, a humanized monoclonal antibody against the IL-6 receptor, may be effective when administered monthly to patients with chronic antibody-mediated rejection...

Detailed Description

Chronic antibody-mediated rejection (ABMR) is now recognized as the leading cause of late kidney transplant failure (1). A number of new immunosuppressive medications have been introduced to the field...

Eligibility Criteria

Inclusion

  • Age ≥18 years
  • Enrolled within six months of biopsy-proven evidence of chronic active ABMR defined by Banff 2017 diagnostic criteria
  • Evidence of DSA detected in the blood within 6 months prior to consent.
  • Able to understand and provide informed consent.

Exclusion

  • Known contraindications for therapy with tocilizumab:
  • Hypersensitivity
  • Elevated liver enzymes
  • Patients at risk for GI perforation
  • Absolute neutrophil count \<500/mm3
  • Platelet count \<50,000/mm3
  • Active infection
  • Contraindications for kidney transplant biopsy, including bleeding diathesis or technical/anatomical infeasibility for biopsy.
  • Contraindications to donor-derived cell-free DNA (AlloSure) testing:
  • Recipient of multiple transplanted organs.
  • Recipient of a transplant from an identical twin.
  • Pregnant
  • Under the age of 18.
  • Less than two weeks post-transplant.

Key Trial Info

Start Date :

March 1 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 31 2025

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT03859388

Start Date

March 1 2019

End Date

December 31 2025

Last Update

April 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection | DecenTrialz